EcoDrugPlus

Notch Receptor 1a

Ensembl ID : ENSMAMG00000017642
Gene Symbol: NOTCH1A
2 Cross references
196 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSMAMG00000012868
Gene Symbol: NOTCH3
3 Cross references
197 Possible Orthologues:

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1

Ensembl ID : ENSMAMG00000013622
Gene Symbol: NFKB1
2 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2-Like 2a

Ensembl ID : ENSMAMG00000025109
Gene Symbol: NFE2L2A
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSMAMG00000014609
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSMAMG00000005945
Gene Symbol: NR1H4
3 Cross references
385 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMAMG00000021400
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSMAMG00000008984
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSMAMG00000013871
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMAMG00000004330
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor, Delta 1a

Ensembl ID : ENSMAMG00000002613
Gene Symbol: OPRD1A
2 Cross references
192 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSMAMG00000023686
Gene Symbol: OPRD1B
3 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).